CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won

Cancer Research and Treatment. 2023;55(1):304-313. Published online 2022 March 30 DOI: https://doi.org/10.4143/crt.2022.004

Cancer Research and Treatment. 2023;55(1):304-313

Link1

Link2 Link3

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) As Conditioning Therapy for Autologous Transplantation in Patients with Relapsed or High Risk Non-Hodgkin Lymphoma: A Multicenter Randomized Phase II Study By the Consortium for Improving Survival of Lymphoma (CISL)

Jong-Ho Won, Kyoung Ha Kim, Seug Yun Yoon, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Sung Kyu Park, JeeHyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun

Transplantation and Cellular Therapy. 2022;28(3):S408-S409

Link1 Link2

P-214: Busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma

Sungnam Lim, Seon Yang Park, Yongjun Lee

Clinical Lymphoma Myeloma and Leukemia. 2022;22:S153

Link1 Link2

Busulfan Plus Cyclophosphamide and Etoposide Versus High-Dose Melphalan As Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Sung-Nam Lim

Transplantation and Cellular Therapy. 2023;29(2):S174

Link1 Link2

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

Neelima Vidula, Andrew M. Evens, Irene B. Helenowski, Borko Jovanovic, Jane N. Winter, Jayesh Mehta, Seema Singhal, Stephanie F. Williams, Olga Frankfurt, Jessica K. Altman, Joanne Monreal, Leo I. Gordon

Modern Chemotherapy. 2013;02(04):57-65

Link1 Link2 Link3

Busulfan, Cyclophosphamide, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)?

G. Salem, A.S. Ruppert, Y. Efebera, P. Elder, A. Bingman, S. Penza, L.A. Andritsos, S.M. Devine

Biology of Blood and Marrow Transplantation. 2012;18(2):S246

Link1 Link2

Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma

Do Young Kim, Joo-seop Chung, Jae-Cheol Jo, Su-Hee Cho, Ho-Jin Shin

Annals of Hematology. 2020;99(4):819-828

Link1

Link2 Link3

Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma

Kyoung Ha Kim, Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Cheolwon Suh, Hye Jin Kang, Chul Won Choi, Ho Sup Lee, Sung Hwa Bae, Jinny Park, Eun Kyung Park, Jae‐Yong Kwak, Mark Hong Lee, Byung Woog Kang, Sung‐Kyu Park, Jong‐Ho Won

Transplant International. 2020;33(10):1211-1219

Link1 Link2 Link3 Link4

Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma

Sigal Grisariu, Michael Y. Shapira, Reuven Or, Batia Avni

Clinical Lymphoma Myeloma and Leukemia. 2018;18(4):272-279

Link1 Link2

Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide and Cyclophosphamide for Patients with Advanced Lymphoma

P.J. Tutschka, S.A. Bilgrami, J.M. Feingold, R.L. Edwards, R.D. Bona, B. Naqvi, J. Clive

Acta Haematologica. 2001;105(4):222-232

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.